Eisai got Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients
Posted on17 Feb 2015
Tagsadditional indication approval, approval of an additional pediatric indication, Eisai got Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients, Indication approval for, Lennox-Gastaut Syndrome, Rufinamide, Rufinamide is a triazole derivative
Comments0
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval of an additional pediatric indication for Eisai’s antiepileptic... Read More